New drug combo aims to supercharge immune therapy for lung cancer patients

This early-phase study tested whether adding the drug copanlisib to the standard immune therapy durvalumab is safe and can help overcome resistance in people with stage III non-small cell lung cancer that cannot be removed by surgery. Eleven participants who had already received chemotherapy and radiation took part. The main goal was to check for side effects, and researchers also looked at whether the combination helped shrink tumors or delay cancer growth.